| Literature DB >> 29439675 |
Li Wan1, Jingyong Huang2, Haizhen Ni3, Guanfeng Yu3.
Abstract
BACKGROUND: Abdominal aortic aneurysm (AAA) is a common cardiovascular system disease with high mortality. The aim of this study was to identify potential genes for diagnosis and therapy in AAA.Entities:
Keywords: TFs regulatory network; abdominal aortic aneurysm; biomarkers; gene expression; protein-protein interaction network; therapy target
Mesh:
Substances:
Year: 2018 PMID: 29439675 PMCID: PMC5812227 DOI: 10.1186/s12872-018-0766-8
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Three datasets in GEO
| GEO accession | Author | Platform | Samples(P:N) | Year |
|---|---|---|---|---|
| GSE7084 | Tromp G | GPL570[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array;GPL2507Sentrix Human-6 Expression BeadChip | 7:8 | 2007 |
| GSE47472 | Biros E | GPL10558Illumina HumanHT-12 V4.0 expression beadchip | 14:8 | 2013 |
| GSE57691 | Biros E | GPL10558Illumina HumanHT-12 V4.0 expression beadchip | 49:10 | 2015 |
P patients, N normal individual
Top 10 up- and down-regulated DEGs
| Gene ID | Gene Symbol | FDR | Combined.ES | Gene ID | Gene Symbol | FDR | Combined.ES |
|---|---|---|---|---|---|---|---|
| Up-regulated genes | Down-regulated genes | ||||||
| 115,362 | GBP5 | 2.46E-07 | 1.718728703 | 5154 | PDGFA | 2.01E-10 | −2.16796797 |
| 3043 | HBB | 5.91E-07 | 1.779962188 | 2063 | NR2F6 | 3.18E-09 | −2.07109705 |
| 3040 | HBA2 | 1.45E-06 | 1.734233872 | 1459 | CSNK2A2 | 3.18E-09 | −2.009947802 |
| 3560 | IL2RB | 4.69E-06 | 1.434746719 | 28,999 | KLF15 | 6.12E-09 | −2.026442955 |
| 4753 | NELL2 | 8.52E-06 | 1.395326 | 7220 | TRPC1 | 7.99E-09 | −1.919770839 |
| 5743 | PTGS2 | 1.01E-05 | 1.378162107 | 81,493 | SYNC | 2.20E-08 | −1.980299756 |
| 84,658 | ADGRE3 | 1.03E-05 | 1.423979214 | 7704 | ZBTB16 | 2.31E-08 | −2.023343723 |
| 8972 | MGAM | 1.37E-05 | 1.372006422 | 116,151 | FAM210B | 4.86E-08 | −1.869732488 |
| 54,504 | CPVL | 1.49E-05 | 1.4454994 | 2308 | FOXO1 | 4.94E-08 | −1.841528166 |
| 1236 | CCR7 | 1.66E-05 | 1.335317111 | 58,499 | ZNF462 | 5.47E-08 | −2.004150438 |
FDR false discovery rate, Combined.ES combined effect size
Fig. 1The heat map of top 50 DEGs. The diagram presents the result of a two-way hierarchical clustering of the top 50 DEGs and samples. The clustering is constructed using the complete-linkage method together with the Euclidean distance. Each row represents a DEG and each column, a sample. The DEG clustering tree is shown on the right. The colour scale illustrates the relative level of DEG expression: red, below the reference channel; green, higher than the reference
Fig. 2Significantly enriched biological processes of DEGs. The x-coordinate axis presents the FDR value. FDR value is more highly, the colour of the bar is more deeply
Fig. 3Significantly enriched molecular functions of DEGs. The x-coordinate axis presents the FDR value. FDR value is more highly, the colour of the bar is more deeply
Fig. 4Significantly enriched cellular components of DEGs. The x-coordinate axis presents the FDR value. FDR value is more highly, the colour of the bar is more deeply
Top 10 GO terms of DEGs
| GO ID | GO term | List in term | Log p |
|---|---|---|---|
| Biological process | |||
| GO:0072359 | circulatory system development | 101/913 | −10.6462 |
| GO:0061061 | muscle structure development | 67/563 | −8.4846 |
| GO:0006413 | translational initiation | 40/268 | −7.9403 |
| GO:0008285 | negative regulation of cell proliferation | 70/643 | −7.2506 |
| GO:0060548 | negative regulation of cell death | 89/910 | −6.8694 |
| GO:0003170 | heart valve development | 12/34 | −6.8435 |
| GO:0007169 | transmembrane receptor protein tyrosine kinase signaling pathway | 89/928 | −6.4948 |
| GO:0070372 | regulation of ERK1 and ERK2 cascade | 34/238 | −6.3893 |
| GO:0006935 | chemotaxis | 81/860 | −5.6514 |
| GO:0060485 | mesenchyme development | 32/237 | −5.5128 |
| Molecular function | |||
| GO:0016491 | oxidoreductase activity | 75/719 | −6.9626 |
| GO:0009055 | electron carrier activity | 21/112 | −6.0854 |
| GO:0019904 | protein domain specific binding | 61/623 | −4.9011 |
| GO:0008092 | cytoskeletal protein binding | 74/810 | −4.7540 |
| GO:0032403 | protein complex binding | 82/928 | −4.6775 |
| GO:0003735 | structural constituent of ribosome | 27/210 | −4.3707 |
| GO:1,901,681 | sulfur compound binding | 27/232 | −3.6356 |
| GO:0016453 | C-acetyltransferase activity | 3/4 | −3.1832 |
| GO:0016634 | oxidoreductase activity, acting on the CH-CH group of donors, oxygen as acceptor | 4/9 | −3.0208 |
| GO:0008565 | protein transporter activity | 14/98 | −2.9919 |
| GO:0016491 | oxidoreductase activity | 75/719 | −6.9626 |
| Cellular component | |||
| GO:0044429 | mitochondrial part | 109/943 | −12.6878 |
| GO:0005925 | focal adhesion | 55/391 | −9.6768 |
| GO:0030529 | intracellular ribonucleoprotein complex | 70/710 | −5.6423 |
| GO:0005759 | mitochondrial matrix | 45/404 | −5.1349 |
| GO:0015629 | actin cytoskeleton | 46/442 | −4.4798 |
| GO:0005901 | caveola | 14/76 | −4.1752 |
| GO:0030663 | COPI-coated vesicle membrane | 6/17 | −3.6750 |
| GO:0044455 | mitochondrial membrane part | 22/173 | −3.6079 |
| GO:0090665 | glycoprotein complex | 6/21 | −3.1162 |
| GO:0044451 | nucleoplasm part | 59/708 | −2.9012 |
List in term: the number of DEGs on the total number of genes in GO term
Log p logarithm processing of p value
The KEGG enrichment signal pathways of DEGs
| KEGG ID | KEGG term | List in term | Log p | Gene list |
|---|---|---|---|---|
| hsa03010 | Ribosome | 22/135 | −6.5000 | FAU,RPL7,RPL9,RPL24,RPL27,RPL30,RPL35A,RPS6,RPS21,UBA52,MRPL33,MRPL19,MRPL18,MRPL22,MRPS16,RSL24D1,MRPL20,MRPS15,MRPS6,MRPS5,MRPL1,MRPL24 |
| hsa00640 | Propanoate metabolism | 10/32 | −5.9097 | ACAT1,ACAT2,LDHA,LDHB,ALDH6A1,MUT,PCCA,SUCLG2,HIBCH,ACSS2,ALDH2,ALDH3A2,HADH,HMGCL,ACO1,GCSH,HOGA1,ESD,PFKM,PRPS2,PHGDH,L2HGDH |
| hsa04510 | Focal adhesion | 23/202 | −4.1028 | ACTN1,CAPN2,CAV2,COL4A1,FLNC,HRAS,ITGA7,LAMA5,LAMC1,PPP1R12A,PDGFA,PDGFRB,MAPK3,PTEN,ROCK1,THBS2,ITGA10,ROCK2,ITGA11,PARVA,PDGFC,TLN2,SHC4,FGF13,MYH10,WASL,ARPC1A,ARHGEF12,GNG12,PIP4K2C |
| hsa04270 | Vascular smooth muscle contraction | 16/120 | −3.8133 | ADCY3,AGTR1,CALD1,EDNRA,GNA11,KCNMB1,MYH11,MYL6,PPP1R12A,MAPK3,PTGIR,ROCK1,ROCK2,RAMP1,ARHGEF12,PPP1R14A |
| hsa00071 | Fatty acid degradation | 9/44 | −3.7701 | ACADL,ACAT1,ACAT2,ADH1A,ADH1B,ALDH2,ALDH3A2,ECI1,HADH,ACYP2,LDHA,LDHB,ACSS2,PFKM,PGM1 |
| hsa03020 | RNA polymerase | 7/31 | −3.3221 | POLR2C,POLR2F,POLR2G,POLR2H,POLR2I,POLR3F,POLR3C,ADCY3,AK1,GUK1,NME3,PGM1,PRPS2,ENPP4,NME7,AK3,NUDT9,POLE4,NT5C3B,CTPS1 |
| hsa05016 | Huntington’s disease | 20/193 | −3.1152 | COX5B,COX6C,COX7A1,COX7B,COX7C,HDAC2,NDUFA4,NDUFA8,NDUFB10,NDUFC1,POLR2C,POLR2F,POLR2G,POLR2H,POLR2I,SOD1,ATP5H,UQCRQ,NDUFA12,NDUFA4L2,UBE2G2,SNCAIP,PINK1,COX17,ATP6V1D,CAPN2,MAPK3,RYR3 |
| hsa05200 | Pathways in cancer | 33/397 | −2.9576 | ADCY3,AGTR1,AR,COL4A1,E2F3,EDNRA,MECOM,FGF13,FOXO1,FZD2,GNA11,GSTP1,MSH6,HDAC2,HRAS,LAMA5,LAMC1,SMAD4,PDGFA,PDGFRB,MAPK3,PTEN,ROCK1,SLC2A1,TCEB1,ZBTB16,FZD3,CCDC6,ROCK2,GNB5,RALBP1,ARHGEF12,GNG12,PDGFC |
| hsa05412 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 10/74 | −2.6366 | ACTN1,CACNB3,CDH2,DAG1,GJA1,ITGA7,RYR2,SGCA,ITGA10,ITGA11 |
| hsa00520 | Amino sugar and nucleotide sugar metabolism | 7/48 | −2.1749 | CYB5R3,GMDS,PGM1,PMM1,UAP1,UGDH,UGP2 |
List in term: the number of DEGs on the total number of genes in GO term
Log p logarithm processing of p value
Fig. 5Significantly enriched vascular smooth muscle contraction signal pathways of DEGs. The red and green diamond represents the up and down-regulated DEGs
Fig. 6Significantly enriched pathways in cancer signal pathways of DEGs. The red and green diamond represents the up and down-regulated DEGs
Fig. 7The TFs networks of the top 20 DEGs. Diamonds and ellipses represent the TFs and target genes, respectively. The red and green colors represent up-regulation and down-regulation, respectively
Top 5 TFs and target genes
| TFs | Number | Target genes |
|---|---|---|
| Oct-1 | 10 | CCR7, CPVL, CSNK2A2, HBB, IL2RB, MGAM, NELL2, TRPC1, ZBTB16, ZNF462 |
| HNF-4 | 10 | CCR7, CPVL, CSNK2A2, HBB, KLF15, MGAM, NELL2, NR2F6, PTGS2, ZNF462 |
| Pax-4 | 8 | ADGRE3, CSNK2A2, FAM210B, NELL2, NR2F6, PDGFA, SYNC, ZBTB16 |
| Evi-1 | 6 | CPVL, GBP5, HBB, NELL2, PTGS2, ZNF462 |
| Nkx2–5 | 6 | CCR7, GBP5, MGAM, NELL2, TRPC1, ZBTB16 |
Fig. 8The PPI networks of the top 20 DEGs. All the diamonds are proteins encoded by the top 20 DEGs and the blue ellipses represent other proteins. The red and green colors represent up-regulation and down-regulation, respectively
Fig. 9The IHC staining of CCR7 in AAA. CCR7 protein expression level detected by immunohistochemistry and photographs was amplified 10 × 20 multiples. Bar = 100 μm. a and c were the case samples from two patients with AAA; b and d were the control sample from two normal individuals. *P<0.05 vs control
Fig. 10The IHC staining of PDGFA in AAA. PDGFA protein expression level detected by immunohistochemistry and photographs was amplified 10 × 20 multiples. Bar = 100 μm. a and c were the case samples from two patients with AAA; b and d were the control sample from two normal individuals. **P<0.01 vs control
Fig. 11The ROC curve analyses of NELL2, CCR7, MGAM, HBB, CSNK2A2, ZBTB16, FOXO1 and PDGFA between AAA and healthy controls